What is it about?
The efficacy of the probiotic, Bacillus coagulans Unique IS2 in the treatment of Irritable Bowel Syndrome (IBS) in children was studied Probiotic treated group showed a significant reduction in pain intensity as compared to the placebo group by the end of the treatment period (8 weeks). There was also a significant improvement in stool consistency as well as reduction in abdominal discomfort, bloating, staining, urgency, incomplete evacuation and passage of gas. This study demonstrates the efficacy of B. coagulans Unique IS2 in reducing the symptoms of Irritable Bowel Syndrome in children in the age group of 4-12 years.
Featured Image
Why is it important?
This study is important as it indicates that B.coagulans Unique IS2 , a stable probiotic requiring no refrigeration is efficaeous in the treatment of IBS in children.
Perspectives
Not many studies have been conducted on the efficacy of probiotics in the treatment of IBS. This study provides evidence that the spore forming probiotic strain , Bacillus coagulans Unique IS2 is useful in the treatment of IBS in children.
Ratna sudha Madempudi
Unique biotech ltd
Read the Original
This page is a summary of: Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study, Beneficial Microbes, June 2018, Wageningen Academic Publishers,
DOI: 10.3920/bm2017.0129.
You can read the full text:
Contributors
The following have contributed to this page
